Mertuzumab

美妥珠（HcHAb18）单抗

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMertuzumab
Drug Alias NameAnti-CD147 chimeric antibody HcHAb18美妥珠单抗（HcHAb18）Metuzumab
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-CD147Antibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsBasigin
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Carcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Pacific Minok Biopharmaceutical Co., Ltd.Institute Of Medicine Fourth Military Medical University
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu Pacific Minok Biopharmaceutical Co., Ltd.Fourth Military Medical University Of Chinese People'S Liberation Army
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Carcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A